Alphabet Spins Out Isomorphic Labs Into $5B Raise at $50B Valuation for AI Drug Discovery

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, is in advanced talks to raise approximately $5 billion at a valuation of roughly $50 billion — a move that would make it one of the highest-valued private biotech companies in history and give it the independent capital to operate at scale outside of Alphabet's balance sheet.

The fundraise signals that investors believe the core promise of AI-driven drug discovery — dramatically compressing the time and cost it takes to bring new treatments to patients — is no longer theoretical. Isomorphic's platform is built on AlphaFold, the protein structure prediction system that won DeepMind a Nobel Prize in 2024 and that researchers worldwide now treat as foundational infrastructure for understanding disease.

Background: What Isomorphic Labs Does

AlphaFold solved a problem that had stumped biologists for 50 years: predicting the three-dimensional shape of a protein from its amino acid sequence. Protein shape determines function. If you know what a disease-causing protein looks like, you can design a molecule that fits into it and disrupts it — that is the basis of most modern drug development.

Isomorphic Labs was formed in 2021 to commercialize that capability and go further: not just predict protein structures, but use AI to design novel molecules that interact with them in therapeutically useful ways. The company has active drug discovery partnerships with Eli Lilly and Novartis, with terms that include milestone payments and royalties on any drugs that reach market.

The company raised a $2.1 billion round led by Thrive Capital in May 2026. The new $5 billion raise, reported by Bloomberg, would bring total outside funding to approximately $7.1 billion. Terms are still in negotiation and the round has not closed.

Why Billion

Drug development is expensive. The industry average cost to bring a single drug from discovery to FDA approval exceeds $2 billion, and the process takes 10–15 years. Most drug candidates fail — roughly 90% of molecules that enter clinical trials never reach patients.

Isomorphic's claim is that AI can improve those odds by:

• Screening billions of potential molecules computationally before spending money on physical synthesis and testing
• Predicting which candidates will fail early based on structural and binding data, cutting late-stage failures
• Designing molecules with specific properties (solubility, stability, selectivity) rather than finding them by trial and error

If that works at scale, the addressable opportunity is enormous. The global pharmaceutical market exceeds $1.5 trillion annually. Shaving even two or three years off the development timeline for a blockbuster drug is worth hundreds of millions of dollars.

The $50 billion valuation reflects investor belief that Isomorphic's platform advantage — built on proprietary training data, years of AlphaFold research, and active pharmaceutical partnerships — creates a durable competitive moat in that market.

Independence From Alphabet

The strategic significance of this round is not just the dollar amount. Raising $5 billion independently means Isomorphic can:

• Hire and retain talent with compensation structures that aren't capped by Alphabet's pay scales
• Pursue partnerships with pharmaceutical companies that might be uncomfortable placing AI drug discovery infrastructure with a Google subsidiary
• Move faster on capital allocation without routing approvals through a parent company

Alphabet retains a stake and the relationship with DeepMind remains close, but Isomorphic would operate with substantially greater autonomy post-close.

What to Watch

The round has not closed, and terms are still in negotiation — meaning valuation and structure could shift. The more consequential near-term milestone is Isomorphic's clinical pipeline: when and whether any of the AI-designed drug candidates from its Lilly or Novartis partnerships enter Phase 1 human trials. A successful first human trial for an AI-designed molecule would validate the entire platform in a way that no fundraise can. Watch for clinical trial registration filings at ClinicalTrials.gov as the leading indicator that the technology is moving from computational to biological proof.